
News|Articles|July 1, 2004
New molecular entity: Rifaximin
This nonsystemic, gastrointestinal-selective oral antibiotic exerts its effect by binding to the beta-subunit of bacterial DNA- dependent RNA polymerase. Rifaximin was approved on May 25, 2004, for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in patients aged 12 years and older.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
New drug class shows promise for geographic atrophy
3
HS patients on biosimilar adalimumab lose response faster than those on the original drug
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































